RNAi modulation of the BCR-ABL fusion gene and uses thereof

Details RNAi modulation of the BCR-ABL fusion gene and uses thereof RNAi modulation of the BCR-ABL fusion gene and uses thereof

2011-08-09

2011-08-09

Bowman, Amy (Department: 1635)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C536S023100, C514S04400A

Reexamination Certificate

active

07994307

ABSTRACT:
The invention relates to compositions and methods for modulating the expression of Bcr-Abl, and more particularly to the down-regulation of Bcr-Abl mRNA and Bcr-Abl protein levels by oligonucleotides via RNA interference, e.g., chemically modified oligonucleotides.

REFERENCES:
patent: 5328470 (1994-07-01), Nabel et al.
patent: 5652222 (1997-07-01), Calabretta et al.
patent: 6107094 (2000-08-01), Crooke
patent: 7196184 (2007-03-01), Heidenreich et al.
patent: 2003/0130186 (2003-07-01), Vargeese et al.
patent: 2003/0143732 (2003-07-01), Fosnaugh et al.
patent: 2003/0190654 (2003-10-01), Heidenreich et al.
patent: 2004/0259247 (2004-12-01), Tuschl et al.
patent: 2005/0107325 (2005-05-01), Manoharan et al.
patent: 2005/0159381 (2005-07-01), McSwiggen et al.
patent: 2007/0004664 (2007-01-01), McSwiggen et al.
patent: 2007/0031844 (2007-02-01), Khvorova et al.
patent: WO 2003/062432 (2003-07-01), None
patent: WO 2003070972 (2003-08-01), None
patent: WO 2004/064737 (2004-08-01), None
patent: WO 2004/080406 (2004-09-01), None
patent: WO 2004/094345 (2004-11-01), None
patent: WO 2005/115481 (2005-12-01), None
Bertrand et al. (Biochemical and Biophysical Research Communications, 2002, 296, pp. 1000-1004).
Elbashir et al. (The EMBO Journal, vol. 20, No. 23, pp. 6877-6888, 2001).
European Search Report for European Patent Application No. EP 09007997.1, Nov. 2, 2009, 6 pages.
Supplementary European Search Report for European Patent Application No. EP 05857009.4, Mar. 23, 2009, 8 pages.
Wohlbold, L., et al., “Repeated application of sequence-specific siRNA molecules leads to an effective downmodulation of all clinically relevant bcr-abl gene variants,” Blood, Nov. 2004, p. 165B, Part 2, vol. 104, No. 11 (Abstract).
Smetsers, T., et al., “An antisense Bcr-Abl phosphodiester-tailed methylphosphonate oligonucleotide reduces the growth of chronic myeloid leukaemia patient cells by a non-antisense mechanism” British Journal of Haematology, 1997, vol. 96, No. 2, 1997, pp. 377-381.
Boese, et al. “Mechanistic Insights Aid Computational Short Interfering RNA Design,” Methods in Enzymology 392:73-96, 2005.
Reynolds, et al. “Rational RNA Design for RNA Interference,” Nature Biotechnology 22:326-330, 2004.
Barnes et al., “Cytogenetic and Molecular Genetic Aspects of Chronic Myeloid Leukaemia” Acta Haematologica 108:180-202 (2002).
Byrom, W.M., et al., “Inducing RNAi with siRNA Cocktails Generated by RNase III” Tech Notes 10 (1), Ambion, Inc., Austin, TX, USA, Mar. (2003).
Castelli et al., A Study of the Interferon Antiviral Mechanism: Apoptosis Activation by the 2-5A System: J. Exp. Med. 186(6):967-972 (1997).
Chen et al., “Stable expression of small interfering RNA sensitizes TEL-PDGF(3R to inhibition with imatinib or rapamycin” J. Clin Invest. 113(12):1784-1791 (2004).
Chen et al., “Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo” Proc. Nat!. Acad. Sci. USA 91:3054-3057 (1994).
Corbin et al., “Analysis of the structural basis of specificity of the Abl kinase by STI571” J. Biol. Chem. 277:32214-32219 (2001).
Damm-Welk, C., et al., “Targeting oncogenic fusion genes in leukemias and lymphomas by RNA interference,” Semin Cancer Biol., 2003, pp. 283-292, vol. 13.
Dohjima, T., et al., “Small interfering RNAs expressed from a Pol III promoter suppress the EWS/FLI-1 transcript in an Ewing sarcoma cell line,” Mol. Ther., 2003, pp. 811-816, vol. 7.
Elbashir et al., “RNA interference is mediated by 21- and 22-nucleotide RNAs” Genes and Dev. 15:188-200 (2001).
Faderl et al., “The Biology and Therapy of Adult Acute Lymphoblastic Leukemia” Cancer (7):1337-1354 (2003).
Fire et al “Potent specific genetic interference by double stranded RNA inCaenorhabditis elegans” Nature 391:806-811 (1998).
Goetz et al., “Requirement for Mdm2 in the Survival Effects of Bcr-Abl and Interleukin 3 in Hematopoietic Cells” Cancer Res. 61:7635-7641 (2001).
Heidel, et al., “Lack of interferon response in animals to naked siRNAs” Nature Biotechn 22 (12):1579-1582 (2004).
Heidenreich et al., “AMLIIMTG8 oncogene suppression by small interfering RNAs supports myeloid differentiation of t8;2I)-positive leukemic cells” Blood 101(8):3157-3163 (2003).
Heisterkamp et al., “Localization of the c-abl oncogene adjacent to a translocation break point in chronic m eloc 'c leukaemia” Nature 306:239-242 1983.
Khvorova, A., et al., “Functional siRNAs and miRNAs exhibit stand bias,” Cell, 2003, pp. 209-216, vol. 115.
Kronenwett R, et al., Kinetic selectivity of complementary nucleic acids: bcr-abl-directed antisense RNA and ribozymes. J Mol Biol. 1996; 259: 632-644.
Kurzrock et al., “Philadelphia Chromosome-Positive Leukemias: From Basic Mechanisms to Molecular Thera eutics” Ann. Intern. Med. 138:819-831 (2003).
Lee et al., “The Interferon-Induced Double-Stranded RNA-Activated Protein Kinase Induces Apoptosis” Virology 199:491-496 (1994).
Li et al., “Specific Killing of Ph Chronic Myeloid Leukemia Cells by a Lentiviral Vector-Delivered Anti-bcr/abl Small Hairpin RNA” Oligonucleotides 13:401-409 (2003).
Limbach et al., “Summary: the modified nucleosides of RNA” Nucleic Acids Res. 22:2183-2196 (1994).
Manche et al., “Interactions between Double-Stranded RNA Regulators and the Protein Kinase DAP” Mol. Cell. Biol. 12(11):5238-5248 (1992).
Mittal, “Improving the Efficiency of RNA Interference in Mammals” Nat. Rev. Genet.5:355-365 (2004).
Novina, C., et al., “The RNAi revolution,” Nature, Jul. 8, 2004, pp. 161-164, vol. 430.
Nowell, P.C., et al., “Radiation Environment in Space” Science 132(3438):1465-1472 (1960).
Nowell, P.C., et al., “A minute chromosome in human chronic granulocytic leukemia,” Science, Nov. 18, 1960, p. 1467, vol. 132, No. 3438.
Nykanen et al., “ATP requirements and small interfering RNA structure in the RNA interference pathway” Cell 107:309-321 (2001).
Ritter et al., “Design and Evaluation of Chemically Synthesized siRNA Targeting the NPM-ALK Fusion Site in Ana plastic Large Cell Lymphoma (ALCL)” Oligonucleotides 13:365-373 (2003).
Rothberg, “Imatinib: resisting the resistance” Leukemia Res. 27:977-978 (2003).
Rowley, “A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining” Nature 243:290-293 (1973).
Scherr et al., “Specific Inhibition of bcr-abl gene expression by small interfering RNA” Blood 101 4:1566-1569 (2003).
Schwarz, D.S., et al., “Asymmetry in the assembly of the RNAi Enzyme complex,” Cell, 2003, pp. 199-208, vol. 115.
Song, E., et al., “RNA interference targeting Fas protects mice from fulminate hepatitis,” Nature Medicine, 2003, pp. 347-351, vol. 9.
Spiller et al., “The Influence of Target Protein Half-Life on the Effectiveness of Antisense Oligonucleotide Analog-Mediated Biologic Responses” Antisense Nucleic Acid Drug Dev. 8:281-293-1998.
Van der Kuip et al., “Adhesion to fibronectin selectively protects Bcr-Abl+ cells from DNA damage-induced apoptosis” Blood 98:1532-1541, 2001.
Westbrook et al., “Clinical Significance of the BCR-ABL Fusion Gene in Adult Acute Lymphoblastic Leukemia: A Cancer and Leukemia Group B Study (8762)” Blood 80:2983-2990 (1992).
Wilda et al., “Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi)” Oncogene 21:5716-5724 (2002).
Wohlbold et al., “Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (ST1571)” Blood 102(6):2236-2239 (2003).
Wilson, J.A., et al., “Induction of RNA interference using short interfering RNA expression vectors in ce

Affiliated with

Also associated with

Rating

RNAi modulation of the BCR-ABL fusion gene and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with RNAi modulation of the BCR-ABL fusion gene and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and RNAi modulation of the BCR-ABL fusion gene and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2717589